# Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct04969731/  
OnCo record `nct04969731` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by GC Cell Corporation, now recruiting.

## Summary

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer is a phase 3 interventional study registered as NCT04969731 by GC Cell Corporation, with 408 participants planned, started 2021-09-07 and due to reach its primary completion in 2026-12. Interventions recorded: Immuncell-LC, Gemcitabine. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04969731
- Phase: 3
- Setting: An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After Resection in Patients With Pancreatic Ductal Adenocarcinoma
- Sponsor: GC Cell Corporation
- Enrolled: 408

## Sources

- ClinicalTrials.gov NCT04969731: https://clinicaltrials.gov/study/NCT04969731

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- companies: [GC Cell](https://onco.cc/companies/gc-cell/)

---
JSON: https://onco.cc/api/v1/entities/nct04969731.json